P3 Health Partners Inc PIII.OQ PIII.O is expected to show a fall in quarterly revenue when it reports results on May 15 for the period ending March 31 2025
The Chicago Illinois-based company is expected to report a 7.8% decrease in revenue to $358.346 million from $388.49 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for P3 Health Partners Inc is for a loss of $8.91 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for P3 Health Partners Inc is $20.00, above its last closing price of $8.45.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -4.10 | -19.50 | Missed | -375.6 | |
Sep. 30 2024 | -1.89 | -1.87 | -14.50 | Missed | -673.3 |
Jun. 30 2024 | -3.47 | -2.50 | -4.50 | Missed | -80 |
Mar. 31 2024 | -5.64 | -5.33 | -8.00 | Missed | -50 |
Dec. 31 2023 | -9.50 | -5.50 | -11.00 | Missed | -100 |
Sep. 30 2023 | -14.55 | -11.00 | -6.00 | Beat | 45.5 |
Jun. 30 2023 | -7.11 | -6.50 | -4.50 | Beat | 30.8 |
Mar. 31 2023 | -31.54 | -33.75 | -11.00 | Beat | 67.4 |
This summary was machine generated May 13 at 20:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。